Head to Head Analysis: Microbot Medical (MBOT) vs. Foamix Pharmaceuticals (FOMX)

Microbot Medical (NASDAQ: MBOT) and Foamix Pharmaceuticals (NASDAQ:FOMX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Microbot Medical and Foamix Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -157.27% -140.17%
Foamix Pharmaceuticals -1,439.32% -54.81% -50.94%

Institutional & Insider Ownership

4.8% of Microbot Medical shares are held by institutional investors. Comparatively, 56.6% of Foamix Pharmaceuticals shares are held by institutional investors. 31.8% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Microbot Medical and Foamix Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 0 1 0 3.00
Foamix Pharmaceuticals 0 0 3 0 3.00

Microbot Medical currently has a consensus price target of $1.75, indicating a potential upside of 110.84%. Foamix Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 64.96%. Given Microbot Medical’s higher probable upside, equities research analysts plainly believe Microbot Medical is more favorable than Foamix Pharmaceuticals.

Volatility and Risk

Microbot Medical has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500. Comparatively, Foamix Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500.

Valuation and Earnings

This table compares Microbot Medical and Foamix Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical $120,000.00 266.98 -$9.66 million ($0.69) -1.20
Foamix Pharmaceuticals $5.53 million 39.66 -$29.33 million ($1.61) -3.64

Microbot Medical has higher earnings, but lower revenue than Foamix Pharmaceuticals. Foamix Pharmaceuticals is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Microbot Medical beats Foamix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Microbot Medical Company Profile

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply